CDR2抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P08143(CDR2 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08143(CDR2 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

CDR2 (Cerebellar Degeneration-Related protein 2) antibodies are autoantibodies associated with paraneoplastic neurological syndromes, particularly paraneoplastic cerebellar degeneration (PCD). These antibodies target the CDR2 protein, a cytoplasmic antigen highly expressed in Purkinje cells of the cerebellum and in certain cancers, such as breast or ovarian tumors. CDR2 antibody-positive PCD often manifests as subacute cerebellar ataxia, dysarthria, and oculomotor disturbances, typically preceding cancer diagnosis.

First identified in the 1990s, CDR2 antibodies are part of the broader family of onconeural antibodies, which arise from immune cross-reactivity between tumor antigens and neural tissues (molecular mimicry). Their presence aids in diagnosing paraneoplastic neurological disorders and guides cancer screening. Mechanistically, CDR2 antibodies may disrupt intracellular signaling, though their direct pathogenic role remains debated, as T-cell-mediated cytotoxicity likely contributes to cerebellar damage.

Detection methods include immunohistochemistry, cell-based assays, or immunoblotting. CDR2 antibodies are distinct from CDR2L (CDR2-like) antibodies linked to gynecologic cancers and retinopathy. Clinically, early recognition of CDR2 antibodies is critical for initiating tumor treatment and immunotherapy (e.g., corticosteroids, IVIG), which may stabilize neurological symptoms. Research continues to explore their pathophysiological mechanisms and therapeutic targets.